OBJECTIVE: Psychological interventions can attenuate distress and enhance coping for those with an initial diagnosis of cancer, but there are few intervention options for individuals with cancer recurrence. To address this gap, we developed and tested a novel treatment combining Mindfulness, Hope Therapy, and biobehavioral components. METHOD: An uncontrolled, repeated measures design was used. Women (N = 32) with recurrent breast or gynecologic cancers were provided 20 treatment sessions in individual (n = 12) or group (n = 20) formats. On average, participants were middle aged (M = 58) and Caucasian (81%). Independent variables (i.e., hope and mindfulness) and psychological outcomes (i.e., depression, negative mood, worry, and symptoms of generalized anxiety disorder) were assessed pre-treatment and 2, 4, and 7 months later. Session-by-session therapy process (positive and negative affect, quality-of-life) and mechanism (use of intervention-specific skills) measures were also included. RESULTS: Distress, anxiety, and negative affect decreased, whereas positive affect and mental-health-related quality-of-life increased over the course of treatment, as demonstrated in mixed-effects models with the intent-to-treat sample. Both hope and mindfulness increased, and use of mindfulness skills was related to decreased anxiety. CONCLUSIONS: This treatment was feasible to deliver and was acceptable to patients. The trial serves as preliminary evidence for a multi-component intervention tailored to treat difficulties specific to recurrent cancer. The blending of the components was novel as well as theoretically and practically consistent. A gap in the literature is addressed, providing directions for testing interventions designed for patients coping with the continuing stressors and challenges of cancer recurrence.
OBJECTIVE: Psychological interventions can attenuate distress and enhance coping for those with an initial diagnosis of cancer, but there are few intervention options for individuals with cancer recurrence. To address this gap, we developed and tested a novel treatment combining Mindfulness, Hope Therapy, and biobehavioral components. METHOD: An uncontrolled, repeated measures design was used. Women (N = 32) with recurrent breast or gynecologic cancers were provided 20 treatment sessions in individual (n = 12) or group (n = 20) formats. On average, participants were middle aged (M = 58) and Caucasian (81%). Independent variables (i.e., hope and mindfulness) and psychological outcomes (i.e., depression, negative mood, worry, and symptoms of generalized anxiety disorder) were assessed pre-treatment and 2, 4, and 7 months later. Session-by-session therapy process (positive and negative affect, quality-of-life) and mechanism (use of intervention-specific skills) measures were also included. RESULTS: Distress, anxiety, and negative affect decreased, whereas positive affect and mental-health-related quality-of-life increased over the course of treatment, as demonstrated in mixed-effects models with the intent-to-treat sample. Both hope and mindfulness increased, and use of mindfulness skills was related to decreased anxiety. CONCLUSIONS: This treatment was feasible to deliver and was acceptable to patients. The trial serves as preliminary evidence for a multi-component intervention tailored to treat difficulties specific to recurrent cancer. The blending of the components was novel as well as theoretically and practically consistent. A gap in the literature is addressed, providing directions for testing interventions designed for patients coping with the continuing stressors and challenges of cancer recurrence.
Authors: Lisa M Thornton; Anna O Levin; Caroline S Dorfman; Neha Godiwala; Carolyn Heitzmann; Barbara L Andersen Journal: Psychooncology Date: 2013-10-14 Impact factor: 3.894
Authors: Sheila N Garland; Linda E Carlson; Alisa J Stephens; Michael C Antle; Charles Samuels; Tavis S Campbell Journal: J Clin Oncol Date: 2014-01-06 Impact factor: 44.544
Authors: Signe R Andersen; Hanne Würtzen; Marianne Steding-Jessen; Jane Christensen; Klaus K Andersen; Henrik Flyger; Cathy Mitchelmore; Christoffer Johansen; Susanne O Dalton Journal: Acta Oncol Date: 2013-01-03 Impact factor: 4.089
Authors: Linda E Carlson; Richard Doll; Joanne Stephen; Peter Faris; Rie Tamagawa; Elaine Drysdale; Michael Speca Journal: J Clin Oncol Date: 2013-08-05 Impact factor: 44.544
Authors: Kelly Yu-Hsin Liao; Nelson C Y Yeung; Celia C Y Wong; Krystal Warmoth; Qian Lu Journal: Support Care Cancer Date: 2016-12-06 Impact factor: 3.603
Authors: Laurie E Steffen; Jennifer S Cheavens; Kevin E Vowles; Jennifer Gabbard; Huynh Nguyen; Gregory N Gan; Martin J Edelman; Bruce W Smith Journal: Support Care Cancer Date: 2019-06-01 Impact factor: 3.603
Authors: Laurie E Steffen; Kevin E Vowles; Bruce W Smith; Gregory N Gan; Martin J Edelman Journal: Health Psychol Date: 2017-11-27 Impact factor: 4.267
Authors: Clark Dumontier; Kerri M Clough-Gorr; Rebecca A Silliman; Andreas E Stuck; André Moser Journal: J Geriatr Oncol Date: 2016-12-13 Impact factor: 3.599
Authors: Jamile A Ashmore; Kirk W Ditterich; Claire C Conley; Melissa R Wright; Peggy S Howland; Kelly L Huggins; Jena Cooreman; Priscilla S Andrews; Donald R Nicholas; Lind Roberts; Larissa Hewitt; Joan N Scales; Jenny K Delap; Christine A Gray; Lynelle A Tyler; Charlotte Collins; Catherine M Whiting; Brittany M Brothers; Marlena M Ryba; Barbara L Andersen Journal: Am Psychol Date: 2018-07-19
Authors: Stephen B Lo; Claire C Conley; Brittany M Brothers; Marlena M Ryba; Georita F Frierson; Rebecca A Shelby; Lisa M Thornton; Kristen M Carpenter; Barbara L Andersen Journal: Health Psychol Date: 2021-07 Impact factor: 5.556
Authors: Laurie E McLouth; Kaitlyn Weyman; Shannon L Golden; Jennifer S Cheavens; Amy Peterman; Vilma Bursac; Jennifer Gabbard; Kathryn E Weaver Journal: Psychooncology Date: 2021-02-26 Impact factor: 3.955